JP2023525100A5 - - Google Patents
Info
- Publication number
- JP2023525100A5 JP2023525100A5 JP2022568601A JP2022568601A JP2023525100A5 JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5 JP 2022568601 A JP2022568601 A JP 2022568601A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutically acceptable
- use according
- compound
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023470P | 2020-05-12 | 2020-05-12 | |
| US63/023,470 | 2020-05-12 | ||
| PCT/IB2021/054013 WO2021229439A1 (en) | 2020-05-12 | 2021-05-11 | Therapeutic combinations comprising a craf inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525100A JP2023525100A (ja) | 2023-06-14 |
| JP2023525100A5 true JP2023525100A5 (cg-RX-API-DMAC7.html) | 2024-05-21 |
Family
ID=75954158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568601A Pending JP2023525100A (ja) | 2020-05-12 | 2021-05-11 | Craf阻害剤を含む治療的組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000789A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4149472A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023525100A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115551509A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202207942A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021229439A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물 |
| GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| DK2884979T3 (da) * | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI839690B (zh) * | 2013-07-12 | 2024-04-21 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合的用途 |
| DK3063143T3 (en) | 2013-11-01 | 2018-08-20 | Novartis Ag | Amino heteroaryl benzamides as kinase inhibitors |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| WO2017037587A1 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Combination of ribociclib and dabrafenib for treating or preventing cancer |
| CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) * | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| TW202023556A (zh) * | 2018-08-27 | 2020-07-01 | 美商庫拉腫瘤技術股份有限公司 | 以mapk路徑抑制劑治療腺癌 |
| CA3123510A1 (en) * | 2018-12-20 | 2020-06-25 | Novartis Ag | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer |
| TW202140029A (zh) * | 2020-02-18 | 2021-11-01 | 瑞士商諾華公司 | 用於治療braf突變型nsclc的包含raf抑制劑之治療組合 |
-
2021
- 2021-05-11 WO PCT/IB2021/054013 patent/WO2021229439A1/en not_active Ceased
- 2021-05-11 US US17/998,391 patent/US20240000789A1/en not_active Abandoned
- 2021-05-11 CN CN202180034241.6A patent/CN115551509A/zh active Pending
- 2021-05-11 JP JP2022568601A patent/JP2023525100A/ja active Pending
- 2021-05-11 EP EP21726201.3A patent/EP4149472A1/en active Pending
- 2021-05-12 TW TW110117160A patent/TW202207942A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gogas et al. | Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management | |
| JP2024133475A5 (cg-RX-API-DMAC7.html) | ||
| JP2024133474A5 (cg-RX-API-DMAC7.html) | ||
| Cavallini et al. | Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy | |
| JP2018519340A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516795A (ja) | エベロリムスおよびアムセネストラントを含む組合せ物 | |
| WO2013105088A1 (en) | Combination therapy for the treatment of cancer | |
| JP2019517587A5 (cg-RX-API-DMAC7.html) | ||
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| US20240398809A1 (en) | Treatment of alopecia areata | |
| EP4580631A1 (en) | Dosage regimens of estrogen receptor degraders | |
| JP2022116304A (ja) | 血液がんの治療のためのPPARγアゴニスト | |
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| CN104039148A (zh) | 组合als疗法 | |
| TW202207942A (zh) | 包含craf抑制劑的治療組合 | |
| EP4106756A1 (en) | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc | |
| JP2020516663A5 (cg-RX-API-DMAC7.html) | ||
| US8765720B2 (en) | Combination therapy for the treatment of multiple myeloma | |
| JP2006508118A5 (cg-RX-API-DMAC7.html) | ||
| JP2024502821A5 (cg-RX-API-DMAC7.html) | ||
| US11406627B2 (en) | Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| US11179395B2 (en) | Treating melanoma with mebendazole and a mitogen-activated kinase inhibitor | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| Weiss et al. | Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial |